Serum level of interleukin-13 receptor alpha 2 in infants with biliary atresia - is it of value?
| Autor: | Mohammed A. Khedr, Haidy Mohammed Zakaria, Nermin M. Adawy, Hanaa A. El-Araby, Alif Allam, Yasmine Ibrahim, Soha Z. El-Shenawy |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Original Paper Hepatology business.industry interleukin-13Rα2 biliary atresia Interleukin-13 receptor medicine.disease Gastroenterology Liver disease Cholestasis Fibrosis Biliary atresia Internal medicine medicine Alpha-2 adrenergic receptor Neonatal cholestasis business Receptor cholestasis Kasai portoenterostomy liver fibrosis |
| Zdroj: | Clinical and Experimental Hepatology |
| ISSN: | 2392-1099 |
| Popis: | Aim of the study We aimed to assess the utility of serum level IL-13Rα2 receptors as a non-invasive marker for early diagnosis of biliary atresia (BA) and selection of BA patients indicated for Kasai portoenterostomy. Material and methods The study included 60 infants with neonatal cholestasis in three groups; early BA group (n = 20), delayed BA group (n = 20) and non-BA cholestasis group (n = 20). A fourth group of 20 healthy neonates (n = 20) served as controls. IL-13Rα2 was measured by enzyme-linked immunosorbent assay in all patients and controls. Results The mean value of IL-13Rα2 was significantly higher in delayed BA group (11.05 ± 10.9 ng/ml) compared to early BA (0.34 ± 0.37 ng/ml), non-BA (0.54 ± 0.85 ng/ml) and control (0.24-0.2 ng/ml) groups. The levels of serum IL-13Rα2 increase with the severity of the degree of fibrosis. IL-13Rα2 at a cutoff level > 0.782 ng/ml could predict late fibrosis with accuracy of 77.55% (p < 0.0001). IL-13Rα2 could differentiate between preserved and disturbed liver architecture at a cut off value of more than 0.42 ng/ml with an accuracy of 81.6%. Conclusions Serum IL-13Rα2 not a diagnostic marker for BA however it could be used as a noninvasive marker for detection of advanced liver fibrosis and presence of disturbed liver architecture that helps in patient selection for undergoing Kasai operation. Serum IL-13Rα2 could be a future therapeutic target for management of BA patients and any fibrotic liver disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|